Neurosterix

Neurosterix company information, Employees & Contact Information

Explore related pages

Related company profiles:

Neurosterix is a biopharmaceutical company focused on developing allosteric modulators for the treatment of neurological disorders. Our drug discovery and development platform identifies and develops allosteric modulators — molecules that increase or decrease the activity of target receptors by binding outside of the “active site” where endogenous ligands and traditional drugs operate. Through this platform, Neurosterix’s novel drug candidates have the potential to provide medicines with improved efficacy, safety and tolerability for patient communities suffering from underserved neurological disorders.

Company Details

Employees
20
Founded
-
Address
Chemin Des Mines 9, Geneva,geneva 1202,switzerland
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Geneva, Geneva
Looking for a particular Neurosterix employee's phone or email?

Neurosterix Questions

News

Neurosterix launches with $63M to Advance Allosteric Modulator Therapeutics for Neurological Disorders - Business Wire

Neurosterix launches with $63M to Advance Allosteric Modulator Therapeutics for Neurological Disorders Business Wire

Addex spinoff Neurosterix debuts with $63m for developing neurological therapies - Pharmaceutical Technology

Addex spinoff Neurosterix debuts with $63m for developing neurological therapies Pharmaceutical Technology

Addex and Perceptive Launch Neurosterix with $63 Million to - GlobeNewswire

Addex and Perceptive Launch Neurosterix with $63 Million to GlobeNewswire

Neurosterix Launches with $63M Series A Financing - Contract Pharma

Neurosterix Launches with $63M Series A Financing Contract Pharma

Neurosterix emerges with $63m for neuroscience pipeline - pharmaphorum

Neurosterix emerges with $63m for neuroscience pipeline pharmaphorum

Addex Therapeutics launches spin-off Neurosterix in Geneva with USD 63 million investment - Greater Geneva Bern area

Addex Therapeutics launches spin-off Neurosterix in Geneva with USD 63 million investment Greater Geneva Bern area

Neurosterix launches with $63 million to advance allosteric modulator therapeutics - Healio

Neurosterix launches with $63 million to advance allosteric modulator therapeutics Healio

Addex Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Addex Reports Full Year 2024 Financial Results and Provides Corporate Update GlobeNewswire

Leading innovation: 10 promising European startups focusing on biopharmaceuticals - EU-Startups

Leading innovation: 10 promising European startups focusing on biopharmaceuticals EU-Startups

Top Neurosterix Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant